Cargando…

Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability

INTRODUCTION: The structural and dynamic determinants that confer highly selective RET kinase inhibition are poorly understood. OBJECTIVES: To explore the druggability landscape of the RET active site in order to uncover structural and dynamic vulnerabilities that can be therapeutically exploited. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shehata, Moustafa A., Contreras, Julia, Martín-Hurtado, Ana, Froux, Aurane, Mohamed, Hossam Taha, El-Sherif, Ahmed A., Plaza-Menacho, Iván
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006619/ https://www.ncbi.nlm.nih.gov/pubmed/35595215 http://dx.doi.org/10.1016/j.jare.2022.05.004

Ejemplares similares

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans
por: Plaza-Menacho, Iván, et al.
Publicado: (2014)

RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements
por: Plaza-Menacho, Iván, et al.
Publicado: (2016)

Cryptic binding sites on proteins: definition, detection, and druggability
por: Vajda, Sandor, et al.
Publicado: (2018)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications
por: Cording, Amy, et al.
Publicado: (2016)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas
por: Krishnan, Aswini, et al.
Publicado: (2020)

Druggable Transient Pockets in Protein Kinases
por: Umezawa, Koji, et al.
Publicado: (2021)

Targeting the cryptic sites: NMR-based strategy to improve protein druggability by controlling the conformational equilibrium
por: Mizukoshi, Yumiko, et al.
Publicado: (2020)

Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites
por: Merritt, Christopher, et al.
Publicado: (2014)

Discovery of the Cryptic Sites of SARS-CoV-2 Papain-like Protease and Analysis of Its Druggability
por: Qiu, Yue, et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

RET kinase alterations in targeted cancer therapy
por: Liu, Xuan, et al.
Publicado: (2020)

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
por: Mahato, Arun Kumar, et al.
Publicado: (2020)

Revealing druggable cryptic pockets in the Nsp1 of SARS-CoV-2 and other β-coronaviruses by simulations and crystallography
por: Borsatto, Alberto, et al.
Publicado: (2022)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors
por: Ferreira, Rubén, et al.
Publicado: (2015)

Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
por: Jordan, Allan M., et al.
Publicado: (2016)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
por: Francavilla, Chiara, et al.
Publicado: (2017)

How many kinases are druggable? A review of our current understanding
por: Anderson, Brian, et al.
Publicado: (2023)

Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linking
por: Dubey, Badri N., et al.
Publicado: (2016)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway
por: Lin, Chen, et al.
Publicado: (2016)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
por: Qin, Anna, et al.
Publicado: (2021)

Mutability of druggable kinases and pro-inflammatory cytokines by their proximity to telomeres and A+T content
por: McKnight, Ian, et al.
Publicado: (2023)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Integrated proteomics and phosphoproteomics revealed druggable kinases in neoadjuvant chemotherapy resistant tongue cancer
por: George, Irene A., et al.
Publicado: (2022)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Moccia, Marialuisa, et al.
Publicado: (2021)

Ret receptor tyrosine kinase sustains proliferation and tissue maturation in intestinal epithelia
por: Perea, Daniel, et al.
Publicado: (2017)

Structure, function and druggability of the African trypanosome flagellum
por: Sáez Conde, Julia, et al.
Publicado: (2022)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Binding of EphrinA5 to RET receptor tyrosine kinase: An in vitro study
por: Liu, Yixin, et al.
Publicado: (2018)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8bc8egbqmp5ope55r7qj7ds3ko